Growth arrested live-attenuated Leishmania infantum KHARON1 null mutants display cytokinesis defect and protective immunity in mice

[1]  F. Gay,et al.  Leishmaniasis , 2019, The Lancet.

[2]  P. Dagur,et al.  Live Attenuated Leishmania donovani Centrin Gene–Deleted Parasites Induce IL-23–Dependent IL-17–Protective Immune Response against Visceral Leishmaniasis in a Murine Model , 2018, The Journal of Immunology.

[3]  V. Simonyan,et al.  Whole genome sequencing of live attenuated Leishmania donovani parasites reveals novel biomarkers of attenuation and enables product characterization , 2017, Scientific Reports.

[4]  D. C. Miguel,et al.  The iron-dependent mitochondrial superoxide dismutase SODA promotes Leishmania virulence , 2017, The Journal of Biological Chemistry.

[5]  J. M. Requena,et al.  Vaccination with a Leishmania infantum HSP70-II null mutant confers long-term protective immunity against Leishmania major infection in two mice models , 2017, PLoS neglected tropical diseases.

[6]  R. Madhubala,et al.  The mitochondrial SIR2 related protein 2 (SIR2RP2) impacts Leishmania donovani growth and infectivity , 2017, PLoS neglected tropical diseases.

[7]  Uma S. Dubey,et al.  Gene deleted live attenuated Leishmania vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response in human PBMCs , 2016, Scientific Reports.

[8]  E. Gluenz,et al.  KHARON Is an Essential Cytoskeletal Protein Involved in the Trafficking of Flagellar Membrane Proteins and Cell Division in African Trypanosomes* , 2016, The Journal of Biological Chemistry.

[9]  P. Dagur,et al.  Live Attenuated Leishmania donovani Centrin Knock Out Parasites Generate Non-inferior Protective Immune Response in Aged Mice against Visceral Leishmaniasis , 2016, PLoS neglected tropical diseases.

[10]  Sarman Singh,et al.  Possibilities and challenges for developing a successful vaccine for leishmaniasis , 2016, Parasites & Vectors.

[11]  S. Teixeira,et al.  Amastin Knockdown in Leishmania braziliensis Affects Parasite-Macrophage Interaction and Results in Impaired Viability of Intracellular Amastigotes , 2015, PLoS pathogens.

[12]  J. Alvar,et al.  Cytokine Release Assays as Tests for Exposure to Leishmania, and for Confirming Cure from Leishmaniasis, in Solid Organ Transplant Recipients , 2015, PLoS neglected tropical diseases.

[13]  E. Gluenz,et al.  Kharon1 Null Mutants of Leishmania mexicana Are Avirulent in Mice and Exhibit a Cytokinesis Defect within Macrophages , 2015, PloS one.

[14]  P. Dagur,et al.  Genetically Modified Live Attenuated Leishmania donovani Parasites Induce Innate Immunity through Classical Activation of Macrophages That Direct the Th1 Response in Mice , 2015, Infection and Immunity.

[15]  Ines Kevric,et al.  New World and Old World Leishmania Infections: A Practical Review. , 2015, Dermatologic clinics.

[16]  R. Madhubala,et al.  Genetically Engineered Ascorbic acid-deficient Live Mutants of Leishmania donovani induce long lasting Protective Immunity against Visceral Leishmaniasis , 2015, Scientific Reports.

[17]  P. Leprohon,et al.  Intrachromosomal Amplification, Locus Deletion and Point Mutation in the Aquaglyceroporin AQP1 Gene in Antimony Resistant Leishmania (Viannia) guyanensis , 2015, PLoS neglected tropical diseases.

[18]  S. Gannavaram,et al.  Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum. , 2015, Vaccine.

[19]  M. A. Reis,et al.  Nutritional Recovery Promotes Hypothalamic Inflammation in Rats during Adulthood , 2014, Mediators of inflammation.

[20]  N. M. Silva,et al.  IL-17-Expressing CD4+ and CD8+ T Lymphocytes in Human Toxoplasmosis , 2014, Mediators of inflammation.

[21]  S. Gannavaram,et al.  Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis. , 2014, Vaccine.

[22]  R. Gazzinelli,et al.  Clinical and Parasitological Protection in a Leishmania infantum-Macaque Model Vaccinated with Adenovirus and the Recombinant A2 Antigen , 2014, PLoS neglected tropical diseases.

[23]  N. Ali,et al.  Genetically Modified Organisms and Visceral Leishmaniasis , 2014, Front. Immunol..

[24]  S. Rafati,et al.  Live Vaccination Tactics: Possible Approaches for Controlling Visceral Leishmaniasis , 2014, Front. Immunol..

[25]  S. Landfear,et al.  KHARON1 Mediates Flagellar Targeting of a Glucose Transporter in Leishmania mexicana and Is Critical for Viability of Infectious Intracellular Amastigotes* , 2013, The Journal of Biological Chemistry.

[26]  D. Liggitt,et al.  Trypanosoma cruzi trans-sialidase initiates a program independent of the transcription factors RORγt and Ahr that leads to IL-17 production by activated B cells , 2013, Nature Immunology.

[27]  D. Liggitt,et al.  Trypanosoma cruzi trans-sialidase initiates an ROR-γt–AHR-independent program leading to IL-17 production by activated B cells , 2013, Nature immunology.

[28]  P. Dagur,et al.  Live Attenuated Leishmania donovani p27 Gene Knockout Parasites Are Nonpathogenic and Elicit Long-Term Protective Immunity in BALB/c Mice , 2013, The Journal of Immunology.

[29]  S. Sundar,et al.  Leishmaniasis: vaccine candidates and perspectives. , 2012, Vaccine.

[30]  J. Cano,et al.  Leishmaniasis Worldwide and Global Estimates of Its Incidence , 2012, PloS one.

[31]  Jane E. Dalton,et al.  B Cell: T Cell Interactions Occur within Hepatic Granulomas during Experimental Visceral Leishmaniasis , 2012, PloS one.

[32]  S. Roberts.  The genetic toolbox for Leishmania parasites , 2011, Bioengineered bugs.

[33]  P. Kaye,et al.  Visceral leishmaniasis: immunology and prospects for a vaccine. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[34]  S. Gannavaram,et al.  Immunity to Visceral Leishmaniasis Using Genetically Defined Live-Attenuated Parasites , 2011, Journal of tropical medicine.

[35]  P. Kaye,et al.  Leishmaniasis: complexity at the host–pathogen interface , 2011, Nature Reviews Microbiology.

[36]  F. Raymond,et al.  Gene Expression Profiling and Molecular Characterization of Antimony Resistance in Leishmania amazonensis , 2011, PLoS neglected tropical diseases.

[37]  Y. Iwakura,et al.  IL-17 Is Necessary for Host Protection against Acute-Phase Trypanosoma cruzi Infection , 2010, The Journal of Immunology.

[38]  S. Nylén,et al.  Immunological Perspectives of Leishmaniasis , 2010, Journal of global infectious diseases.

[39]  Y. Goto,et al.  Optimized subunit vaccine protects against experimental leishmaniasis. , 2009, Vaccine.

[40]  Thomas Korn,et al.  IL-17 and Th17 Cells. , 2009, Annual review of immunology.

[41]  Naomi L. Dunning.  Leishmania vaccines: from leishmanization to the era of DNA technology , 2009 .

[42]  A. Ouaissi,et al.  Live attenuated Leishmania vaccines: a potential strategic alternative , 2008, Archivum Immunologiae et Therapiae Experimentalis.

[43]  Y. Goto,et al.  Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. , 2007, Vaccine.

[44]  Y. Goto,et al.  Leish-111f, a Recombinant Polyprotein Vaccine That Protects against Visceral Leishmaniasis by Elicitation of CD4+ T Cells , 2007, Infection and Immunity.

[45]  Ashutosh,et al.  Molecular mechanisms of antimony resistance in Leishmania. , 2007, Journal of medical microbiology.

[46]  A. Ponte-Sucre,et al.  Leishmania amazonensis: metabolic adaptations induced by resistance to an ABC transporter blocker. , 2006, Experimental parasitology.

[47]  K. Foulds,et al.  Th1 memory: implications for vaccine development , 2006, Immunological reviews.

[48]  M. Ouellette,et al.  Live Nonpathogenic Parasitic Vector as a Candidate Vaccine against Visceral Leishmaniasis , 2005, Infection and Immunity.

[49]  C. McKnight,et al.  High-resolution crystal structures of villin headpiece and mutants with reduced F-actin binding activity. , 2005, Biochemistry.

[50]  K. Figarella,et al.  Substrate preferences and glucose uptake in glibenclamide-resistant Leishmania parasites. , 2005, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.

[51]  C. Sousa,et al.  Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function , 2005, Nature Immunology.

[52]  H. Nakhasi,et al.  Centrin Gene Disruption Impairs Stage-specific Basal Body Duplication and Cell Cycle Progression in Leishmania* , 2004, Journal of Biological Chemistry.

[53]  G. H. Coombs,et al.  Cysteine Protease B of Leishmania mexicana Inhibits Host Th1 Responses and Protective Immunity 1 , 2003, The Journal of Immunology.

[54]  G. H. Coombs,et al.  Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines. , 2003, The Journal of infectious diseases.

[55]  S. Beverley,et al.  Improvements in transfection efficiency and tests of RNA interference (RNAi) approaches in the protozoan parasite Leishmania. , 2003, Molecular and biochemical parasitology.

[56]  Michael P. Barrett,et al.  Genetic characterization of glucose transporter function in Leishmania mexicana , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[57]  G. Milon,et al.  Real-Time PCR for Detection and Quantitation of Leishmania in Mouse Tissues , 2002, Journal of Clinical Microbiology.

[58]  M. Ouellette,et al.  Reduced Infectivity of a Leishmania donovani Biopterin Transporter Genetic Mutant and Its Use as an Attenuated Strain for Vaccination , 2002, Infection and Immunity.

[59]  G. Matlashewski,et al.  Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. , 2001, Vaccine.

[60]  D. Das,et al.  Fine Needle Aspiration Cytology Diagnosis of Cutaneous Leishmaniasis in a 6-Month-Old Child , 2001, Acta Cytologica.

[61]  J. Streit,et al.  Protective Immunity Against the Protozoan Leishmania chagasi Is Induced by Subclinical Cutaneous Infection with Virulent But Not Avirulent Organisms1 , 2001, The Journal of Immunology.

[62]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[63]  A. Hill,et al.  Vaccines against intracellular infections requiring cellular immunity , 2000, Nature.

[64]  J. Vandekerckhove,et al.  Villin Function in the Organization of the Actin Cytoskeleton , 1999, The Journal of Biological Chemistry.

[65]  S. Landfear,et al.  Differential Regulation of Multiple Glucose Transporter Genes in Leishmania mexicana * , 1998, The Journal of Biological Chemistry.

[66]  G. Matlashewski,et al.  Loss of virulence in Leishmania donovani deficient in an amastigote-specific protein, A2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[67]  K. Mawhinney,et al.  Standardization of Enzyme-Linked Immunosorbent Assays (ELISAs) for Quantitative Estimation of Antibodies Specific for Infectious Bovine Rhinotracheitis Virus, Respiratory Syncytial Virus, Parainfluenza-3 Virus, and Bovine Viral Diarrhea Virus , 1997, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.

[68]  S. Landfear,et al.  Biochemistry and molecular genetics of Leishmania glucose transporters , 1994, Parasitology.

[69]  R. Titus,et al.  An avirulent lipophosphoglycan-deficient Leishmania major clone induces CD4+ T cells which protect susceptible BALB/c mice against infection with virulent L. major , 1993, Infection and immunity.

[70]  D. Rivier,et al.  Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge , 1993, Parasite immunology.

[71]  J. Cazzulo.  Aerobic fermentation of glucose by trypanosomatids , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[72]  S. Beverley,et al.  Gene replacement in parasitic protozoa , 1990, Nature.

[73]  S. Moncada,et al.  Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. , 1990, Journal of immunology.

[74]  R. Coffman,et al.  Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens , 1988, The Journal of experimental medicine.

[75]  H. Amini,et al.  CONTROL OF ZOONOTIC CUTANEOUS LEISHMANIASIS BY MASS LEISHMANIZATION IN HYPERENDEMIC AREA OF ISFAHAN , 1988 .

[76]  W. Paul,et al.  Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. , 1987, Science.

[77]  J. Berman,et al.  Sodium stibogluconate (Pentostam) inhibition of glucose catabolism via the glycolytic pathway, and fatty acid beta-oxidation in Leishmania mexicana amastigotes. , 1987, Biochemical pharmacology.

[78]  T. Boon,et al.  A limiting dilution assay for quantifying Leishmania major in tissues of infected mice , 1985, Parasite immunology.

[79]  R. Gorczynski.  Immunization of susceptible BALB/c mice against Leishmania braziliensis. II. Use of temperature-sensitive avirulent clones of parasite for vaccination purposes. , 1985, Cellular immunology.

[80]  E. Handman,et al.  Vaccination against cutaneous leishmaniasis in mice using nonpathogenic cloned promastigotes of Leishmania major and importance of route of injection. , 1984, The Australian journal of experimental biology and medical science.

[81]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[82]  S. Maeda,et al.  IVbteA Modified Colorimetric MTT Assay Adapted fbr Application to Proliferation and Cytotoxicity Assays , 2018 .

[83]  D. Das,et al.  Fine needle aspiration cytology diagnosis of cutaneous leishmaniasis in a 6-month-old child: a case report. , 2001, Acta cytologica.

[84]  E. Javadian,et al.  The experience of leishmanization in the Islamic Republic of Iran. , 1997 .

[85]  D. C. Henckel,et al.  Case report. , 1995, Journal.

[86]  Curley,et al.  A Practical Review , 2022 .